Recipharm completes acquisition of majority stake in Nitin Lifesciences

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Vice president

Recipharm has completed the acquisition of a majority stake in India’s Nitin Lifesciences in a deal the Swedish contractor says strengthens its presence in an important market.

Plans for the transaction – which saw Recipharm pay SEK824m ($101m) for a 74% stake in Nitin – were announced last October​ when executive vice president Mark Quick told us the fast growing Indian market is attractive to the CMO’s customers.

Recipharm paid for its Nitin stake partly through a fundraising round conducted in January that saw it issue 2,250,000 shares and raise a total of SEK276m.

CEO Thomas Eldred reiterated the CMOs interest in the Indian market, describing the completion of the deal as “an important step in the development of both companies​.”


In addition to expanding Recipharm’s global reach, the deal also strengthens the CMOs capabilities in sterile injectables and lyophilization he said.

The deal is part of the growth strategy Recipharma adopted when it went public in June 2014​.

Since then the CMO has bought Italian firm Corvette​ and Portuguese contractor Lusomedicamenta​.

It has also bought a plant in France from Flamel Technologies​, invested in chemistry specialist Synthonics​, acquired a stake in Pharmanest​ and is set to buy a manufacturing facility from Alcon​.

Related news

Show more

Related product

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more